Scientists have reported the safety and efficacy of the interoperable Artificial Pancreas System smartphone app (iAPS). The app can interface wirelessly with leading continuous glucose monitors (CGM), insulin pump devices, and decision-making algorithms.
The clinical trial and the app, which runs on an unlocked smartphone, are described in an article published in Diabetes Technology & Therapeutics (DTT), a peer-reviewed journal from Mary Ann Liebert, Inc., publishers. Click here to read the full-text article free on the Diabetes Technology & Therapeutics (DTT).
Eyal Dassau, Harvard University (Cambridge, MA), Sansum Diabetes Research Institute (Santa Barbara, CA), and Joslin Diabetes Center (Boston, MA), and colleagues from these institutions and Labrasoft LLC (Leander, TX) coauthored the article entitled "Design and Clinical Evaluation of the Interoperable Artificial Pancreas System (iAPS) Smartphone App: Interoperable Components with Modular Design for Progressive Artificial Pancreas Research and Development."